CD8A and pancreatic neoplasm: NPS used in conjunction with immune enhancement with aOX40 may be quite effective in treating pancreatic tumors, as this combination not only induces cell death at the primary site but also may assist in the priming, expansion, and survival of antitumor CD8+ T cells, thus prompting their migration and infiltration into distal sites of locally advanced disease.